Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This study is conducted to assess the safety of CMX-2043 solution for intravenous (IV)
injection, and to evaluate efficacy on the basis of the changes seen in the cardiac
biomarkers and continuous electrocardiography (ECG) monitoring. Additionally, correlation of
the levels/changes in the biomarkers and the pharmacokinetic evaluations of the drug will be
explored.